I'm LongbridgeAI, I can summarize articles.SZN-8141, a dual Wnt/VEGF modulator, is entering clinical trials for retinal diseases, with the DUET study set to compare it to Vabysmo and focus on efficacy, durability, and retinal reperfusion. Strong IP, robust financing, and a pipeline including SZN-8143 and a candidate for Fuchs' dystrophy support growth.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
SZN-8141, a dual Wnt/VEGF modulator, is entering clinical trials for retinal diseases, with the DUET study set to compare it to Vabysmo and focus on efficacy, durability, and retinal reperfusion. Strong IP, robust financing, and a pipeline including SZN-8143 and a candidate for Fuchs' dystrophy support growth.
Based on